The use of nivolumab improved 4- and 5-year overall survival three-fold in patients with kidney cancer, according to data presented at the ASCO Annual Meeting. This is terrific for patients of this difficult disease, as well as for Bristol-Meyers Squibb who markets Optivo.   Nivolumad therapy in kidney cancer